At the same time, proliferative markers such as MKI67, TOP2A, PRC1 and RRM2 underscore the importance of cell-cycle dynamics not only in tumor growth but also potentially within rapidly expanding immune subsets that contribute to treatment efficacy37–40. This evidence concerns the gene PRC1 and neoplasm.